Aradigm Corporation Company Profile (NASDAQ:ARDM)

About Aradigm Corporation

Aradigm Corporation logoAradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ARDM
  • CUSIP:
Key Metrics:
  • Previous Close: $1.95
  • 50 Day Moving Average: $1.94
  • 200 Day Moving Average: $3.84
  • 52-Week Range: $1.47 - $7.19
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.79
  • P/E Growth: 0.00
  • Market Cap: $28.83M
  • Outstanding Shares: 14,786,000
  • Beta: 1.14
Profitability:
  • Net Margins: -32,717.14%
  • Return on Equity: -220.57%
  • Return on Assets: -105.09%
Debt:
  • Debt-to-Equity Ratio: 1.53%
  • Current Ratio: 5.27%
  • Quick Ratio: 5.27%
Additional Links:
Companies Related to Aradigm Corporation:

Analyst Ratings

Consensus Ratings for Aradigm Corporation (NASDAQ:ARDM) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Aradigm Corporation (NASDAQ:ARDM)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Aradigm Corporation (NASDAQ:ARDM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
8/10/2016Q2($0.59)($0.59)ViewN/AView Earnings Details
5/10/2016Q1($0.59)($0.55)ViewN/AView Earnings Details
3/15/2016Q415($0.55)($0.63)ViewN/AView Earnings Details
11/11/2015Q3($0.19)($0.38)ViewN/AView Earnings Details
8/13/2015Q2($0.08)($0.08)$11.60 million$10.00 millionViewN/AView Earnings Details
5/11/2015Q1($0.06)($0.08)ViewN/AView Earnings Details
3/17/2015Q414($0.07)($0.06)$6.70 million$8.10 millionViewN/AView Earnings Details
11/7/2014Q314($0.10)($0.06)$4.80 million$6.60 millionViewN/AView Earnings Details
8/7/2014Q214($0.09)($0.09)$4.25 million$12.20 millionViewN/AView Earnings Details
10/28/2013Q3 13($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aradigm Corporation (NASDAQ:ARDM)
Current Year EPS Consensus Estimate: $-2.06 EPS
Next Year EPS Consensus Estimate: $-1.09 EPS

Dividends

Dividend History for Aradigm Corporation (NASDAQ:ARDM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aradigm Corporation (NASDAQ:ARDM)
Insider Ownership Percentage: 4.10%
Institutional Ownership Percentage: 43.59%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/4/2016Juergen Kurt FroehlichInsiderSell423$6.76$2,859.48View SEC Filing  
6/21/2016Juergen Kurt FroehlichInsiderSell333$4.45$1,481.85View SEC Filing  
12/13/2013Virgil ThompsonDirectorSell3,340$0.17$567.80View SEC Filing  
8/27/2013First Eagle Investment ManagemMajor ShareholderBuy40,322,580$0.12$4,838,709.60View SEC Filing  
12/11/2012First Eagle Investment ManagemMajor ShareholderBuy41,666,667$0.12$5,000,000.04View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aradigm Corporation (NASDAQ:ARDM)
DateHeadline
finance.yahoo.com logoAradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017 on February 13 (NASDAQ:ARDM)
finance.yahoo.com - February 9 at 3:40 PM
News IconAradigm Corp ARDM Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ARDM)
www.bioportfolio.com - January 7 at 9:03 PM
finance.yahoo.com logoAradigm to Present at 9th Annual Biotech Showcase Conference on January 9 (NASDAQ:ARDM)
finance.yahoo.com - January 6 at 3:43 PM
News IconArthur J. Gallagher & Co. (AJG) Shares Bought by the Bollard Group LLC (NASDAQ:ARDM)
vouxmagazine.com - January 4 at 9:20 PM
4-traders.com logoGrifols : to buy Hologic's stake in blood screening JV for $1.85 billion (NASDAQ:ARDM)
www.4-traders.com - December 15 at 4:07 PM
biz.yahoo.com logoARADIGM CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:ARDM)
biz.yahoo.com - December 6 at 12:40 PM
investopedia.com logoAradigm's Inhaled Antibiotic Fails Study (ARDM) (NASDAQ:ARDM)
www.investopedia.com - December 3 at 8:44 AM
investopedia.com logoAradigm Lung Infection Antibiotic Fails Trial (ARDM) (NASDAQ:ARDM)
www.investopedia.com - December 2 at 9:01 PM
insidermonkey.com logoDon’t Write Off Aradigm Corporation (ARDM) Just Yet (NASDAQ:ARDM)
www.insidermonkey.com - December 2 at 4:00 PM
businesswire.com logoAradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Lung Infections ... (NASDAQ:ARDM)
www.businesswire.com - December 1 at 3:41 PM
stockhouse.com logoMid-Afternoon Market Update: NASDAQ Down 1.25%; CLARCOR Shares Gain On Acquisition News (NASDAQ:ARDM)
www.stockhouse.com - December 1 at 3:41 PM
nasdaq.com logoMid-Day Market Update: Crude Oil Up Over 4%; Express Shares Fall On Weak Outlook (NASDAQ:ARDM)
www.nasdaq.com - December 1 at 3:41 PM
finance.yahoo.com logoAradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment … (NASDAQ:ARDM)
finance.yahoo.com - December 1 at 3:41 PM
us.rd.yahoo.com logo7:03 am Aradigm announces top-line results from its two Phase 3 clinical trials evaluating the safety and efficacy of Pulmaquin (shares halted) (NASDAQ:ARDM)
us.rd.yahoo.com - December 1 at 3:41 PM
smarteranalyst.com logoStock Update (NASDAQ:ARDM): Why Aradigm Corporation Shares Are Crashing 60% Today (NASDAQ:ARDM)
www.smarteranalyst.com - December 1 at 3:41 PM
finance.yahoo.com logoAradigm posts mixed late-stage data on inhaled antibiotic (NASDAQ:ARDM)
finance.yahoo.com - December 1 at 3:41 PM
marketwatch.com logoAradigm Corp. drops 54% in pre-market trade on results of two late-stage clinical trials (NASDAQ:ARDM)
www.marketwatch.com - December 1 at 3:41 PM
publicnow.com logoAradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Lung Infections with Pseudomonas aeruginosa (NASDAQ:ARDM)
www.publicnow.com - December 1 at 3:41 PM
thestreet.com logoAradigm Shares Plunge After Releasing Mixed Clinical Trial Results For Pulmaquin (NASDAQ:ARDM)
www.thestreet.com - December 1 at 3:41 PM
rttnews.com logoWhat's In The Offing For These Biotech Stocks? (NASDAQ:ARDM)
www.rttnews.com - November 22 at 12:39 PM
News IconAradigm Corporation ARDM Financial and Strategic SWOT Analysis Review Prices from USD $125 (NASDAQ:ARDM)
www.bioportfolio.com - November 22 at 12:39 PM
News IconAradigm Corporation ARDM Medical Equipment Deals and Alliances Profile Prices from USD $250 (NASDAQ:ARDM)
www.bioportfolio.com - November 20 at 8:15 AM
finance.yahoo.com logoARADIGM CORP Financials (NASDAQ:ARDM)
finance.yahoo.com - November 18 at 3:35 PM
marketexclusive.com logoAradigm Corporation (NASDAQ:ARDM) Files An 8-K Announces Third Quarter 2016 Financial Results (NASDAQ:ARDM)
marketexclusive.com - November 11 at 12:59 PM
finance.yahoo.com logoAradigm to Present at the Stifel 2016 Healthcare Conference on November 16 (NASDAQ:ARDM)
finance.yahoo.com - November 10 at 2:05 PM
capitalcube.com logoAradigm Corp. :ARDM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016 (NASDAQ:ARDM)
www.capitalcube.com - November 10 at 2:04 PM
publicnow.com logoAradigm Announces Third Quarter 2016 Financial Results (NASDAQ:ARDM)
www.publicnow.com - November 9 at 12:23 PM
4-traders.com logoAradigm : Multi-million Dollar DTRA Funding for Biodefense Research with Aradigm's Inhaled Ciprofloxacin (NASDAQ:ARDM)
www.4-traders.com - October 18 at 8:23 AM
uk.finance.yahoo.com logoMulti-million Dollar DTRA Funding for Biodefense Research with Aradigm’s Inhaled Ciprofloxacin (NASDAQ:ARDM)
uk.finance.yahoo.com - October 18 at 8:23 AM
publicnow.com logoMulti-million Dollar DTRA Funding for Biodefense Research with Aradigm's Inhaled Ciprofloxacin (NASDAQ:ARDM)
www.publicnow.com - October 18 at 8:23 AM
publicnow.com logoAradigm Announces Australian Research Council Funding to Develop Nanotechnologies Targeting Bacterial and Fungal Biofilms (NASDAQ:ARDM)
www.publicnow.com - October 7 at 8:22 AM
News IconAradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-3) (NASDAQ:ARDM)
www.pharmiweb.com - September 24 at 8:51 AM
fxpips.com logoManufacturing Stocks Review – Winners and Losers (NASDAQ:ARDM)
www.fxpips.com - September 23 at 8:24 AM
rttnews.com logoARDM Awaits Data In Q4, FDA Clears TCMD Device, Newfound Interest For GLMD, GALT (NASDAQ:ARDM)
www.rttnews.com - September 23 at 8:24 AM
finance.yahoo.com logo3 Reasons Why Aradigm Corporation (ARDM) is a Great Momentum Stock (NASDAQ:ARDM)
finance.yahoo.com - September 22 at 3:31 PM
News IconAradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin ... (NASDAQ:ARDM)
www.biomedreports.com - September 22 at 9:26 AM
News IconAradigm Corporation To Present At The 2016 Healthcare Conference On September 27 (NASDAQ:ARDM)
www.biospace.com - September 22 at 9:26 AM
nasdaq.com logoAradigm (ARDM) Shares March Higher, Can It Continue? (NASDAQ:ARDM)
www.nasdaq.com - September 22 at 9:26 AM
News IconAradigm Announces Last Patient Dosing Visit in ORBIT-3 & ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchie... (NASDAQ:ARDM)
www.advfn.com - September 22 at 9:26 AM
publicnow.com logoAradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis Patients (NASDAQ:ARDM)
www.publicnow.com - September 22 at 9:26 AM
publicnow.com logoAradigm to Host Analyst Meeting and Webcast on September 26 in New York City (NASDAQ:ARDM)
www.publicnow.com - September 21 at 8:49 AM
finance.yahoo.com logoAradigm to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27 (NASDAQ:ARDM)
finance.yahoo.com - September 20 at 9:29 AM
News IconAradigm Corporation (ARDM) - Medical Equipment - Deals and Alliances Profile - New Market Report (NASDAQ:ARDM)
reports.pr-inside.com - September 16 at 3:32 PM
News IconNewly released market study: Stille AB (STIL) - Medical Equipment - Deals and Alliances Profile (NASDAQ:ARDM)
reports.pr-inside.com - September 15 at 12:28 PM
capitalcube.com logoAradigm Corp. :ARDM-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:ARDM)
www.capitalcube.com - August 12 at 12:07 PM
sg.finance.yahoo.com logoAradigm reports 2Q loss (NASDAQ:ARDM)
sg.finance.yahoo.com - August 10 at 9:40 AM
publicnow.com logoAradigm Announces Second Quarter 2016 Financial Results (NASDAQ:ARDM)
www.publicnow.com - August 10 at 9:40 AM
biz.yahoo.com logoARADIGM CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:ARDM)
biz.yahoo.com - June 10 at 5:02 PM
capitalcube.com logoAradigm Corp. :ARDM-US: Earnings Analysis: Q1, 2016 By the Numbers (NASDAQ:ARDM)
www.capitalcube.com - May 17 at 12:15 PM
finance.yahoo.com logoTwo Presentations on Aradigm’s Inhaled Liposomal Ciprofloxacin Programs at the American Thoracic Society 2016 International Conference (NASDAQ:ARDM)
finance.yahoo.com - May 11 at 7:00 AM

Social

What is Aradigm Corporation's stock symbol?

Aradigm Corporation trades on the NASDAQ under the ticker symbol "ARDM."

When will Aradigm Corporation announce their earnings?

Aradigm Corporation is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

Who owns Aradigm Corporation stock?

Aradigm Corporation's stock is owned by many different of institutional and retail investors. Top institutional shareholders include First Eagle Investment Management, LLC (29.70%), Boxer Capital LLC (4.29%), Paulson & CO. Inc. (1.30%) and FMR LLC (1.14%).

Who sold Aradigm Corporation stock? Who is selling Aradigm Corporation stock?

Aradigm Corporation's stock was sold by a variety of institutional investors in the last quarter, including Boxer Capital LLC.

Who bought Aradigm Corporation stock? Who is buying Aradigm Corporation stock?

Aradigm Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Paulson & CO. Inc..

How do I buy Aradigm Corporation stock?

Shares of Aradigm Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Aradigm Corporation stock cost?

One share of Aradigm Corporation stock can currently be purchased for approximately $1.95.

Aradigm Corporation (NASDAQ:ARDM) Chart for Wednesday, March, 1, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Aradigm Corporation (NASDAQ:ARDM)

Earnings History Chart

Earnings by Quarter for Aradigm Corporation (NASDAQ:ARDM)

Dividend History Chart

Dividend Payments by Quarter for Aradigm Corporation (NASDAQ:ARDM)

Last Updated on 3/1/2017 by MarketBeat.com Staff